Targets › MET
43 programs from 35 companies in 241 trials: 122 Phase 2, 84 Phase 1, 31 Phase 3, 4 Phase 4; Oncology, Gastroenterology, Immunology; next expected readout Nov 2026.
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. (UniProt, P08581)
Open in Phaseline: the race on MET, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Exelixis | Cabozantinib (XL184) Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor | KDR, MET | Phase 4 | Medullary Thyroid Cancer; Hepatocellular Carcinoma; Metastatic Prostate Cancer; Renal Cell Carcinoma … | Jan 2027 |
| Pfizer | crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 4 | NSCLC | Mar 2028 |
| AstraZeneca | savolitinib Hepatocyte growth factor receptor inhibitor | MET | Phase 3 | Carcinoma; Papillary Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Lung Cancer … | Nov 2026 |
| Exelixis | Zanzalintinib (XL092) Multi-targeted tyrosine kinase inhibitor targeting FGFR, MET, ROS1, and AXL | FGFR1, FGFR2, FGFR3, FGFR4, MET, KIT, PDGFRA | Phase 3 | Non-Clear Cell Renal Cell Carcinoma; Colorectal Cancer; Meningioma; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| National Cancer Institute (NCI) | Cabozantinib S-malate Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor | KDR, MET | Phase 3 | Functioning Pancreatic Neuroendocrine Tumor; Clear Cell Renal Cell Carcinoma; Advanced Bladder Urothelial Carcinoma; Differentiated Thyroid Gland Carcinoma … | Dec 2026 |
| Johnson & Johnson (Janssen) | Amivantamab Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor | EGFR, MET | Phase 3 | Advanced or Metastatic Non-small Cell Lung Cancer; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck … | Dec 2026 |
| Beijing Pearl Biotechnology Limited Liability Company | PLB1001 (Vebreltinib) MET inhibitor | MET | Phase 3 | Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Glioblastoma | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | AL2846 Capsule Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET | MET, KIT, FLT4, RET | Phase 3 | Thyroid Cancer | Jan 2027 |
| IDEAYA Biosciences | Crizotinib Hepatocyte growth factor receptor inhibitor; ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor | MET, ALK, EML4, NPM1, ROS1 | Phase 3 | Uveal Melanoma; Metastatic Uveal Melanoma; ALK Gene Rearrangement; Advanced Lymphoma … | Jan 2027 |
| AbbVie | Telisotuzumab adizutecan Anti-MET antibody-drug conjugate | MET | Phase 3 | Colorectal Cancer; Metastatic Colorectal Cancer; Pancreatobiliary Cancers; Head and Neck Squamous Cell Carcinoma … | Jul 2027 |
| AbbVie | Telisotuzumab Vedotin (ABBV-399) Tubulin inhibitor; Hepatocyte growth factor receptor binding agent | Tubulin, MET | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumors Cancer … | Feb 2028 |
| Apollomics | APL-101 MET inhibitor | MET | Phase 2 | Solid Tumors; Metastatic Non Small Cell Lung Cancer | Nov 2026 |
| Hansoh BioMedical R&D Company | HS-20117-2 Injection EGFR-MET bispecific antibody | EGFR, MET | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer; Solid Tumors; Advanced Solid Tumors | Dec 2026 |
| Eli Lilly | Merestinib (LY2801653) Hepatocyte growth factor receptor inhibitor | MET | Phase 2 | Biliary Tract Cancer | Dec 2026 |
| Sichuan Kelun-Biotech Biopharmaceutical | SKB571 MET inhibitor | MET | Phase 2 | Non-small Lung Cancer; Gastrointestinal Tumors; Lung Cancer (Non-Small Cell); HNSCC … | Dec 2026 |
| Beijing Scitech-Mq Pharmaceuticals | ST-1898 Receptor tyrosine kinase (RTK) inhibitor targeting VEGFR2, c-MET, AXL, PDGFRA, RET, and KI | VEGFR2, MET, AXL, PDGFRA, RET | Phase 2 | Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma; Advanced Renal Cell Carcinoma | Dec 2026 |
| Avistone Biotechnology | Vebreltinib MET inhibitor | MET | Phase 2 | Non-Small-Cell Lung Cancer; Clear Cell Sarcoma (CCS) | Dec 2026 |
| M.D. Anderson Cancer Center | Cabozantinib S-malate Vascular endothelial growth factor receptor 2 inhibitor; Hepatocyte growth factor receptor inhibitor | KDR, MET | Phase 2 | Malignant Neoplasms of Urinary Tract; Locally Advanced Osteosarcoma; Brain Metastases; Advanced Breast Carcinoma … | Apr 2027 |
| Novartis | Capmatinib Hepatocyte growth factor receptor inhibitor | MET | Phase 2 | Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Solid Tumour | Jul 2027 |
| Shanghai EpimAb Biotherapeutics | Bafisontamab (EMB-01) Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor | MET, EGFR | Phase 2 | Metastatic Colorectal Cancer; Unresectable/Metastatic Colorectal Cancer | Dec 2027 |
| Abion | ABN401 (vabametkib) c-MET inhibitor | MET | Phase 2 | Advanced Solid Tumors | Feb 2029 |
| Yonsei University | ABN401 c-MET inhibitor | MET | Phase 2 | Neoplasms | – |
| Merck KGaA | Tepotinib Hepatocyte growth factor receptor inhibitor | MET | Phase 2 | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Advanced Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic … | – |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2922 for injection anti-EGFR/c-Met bispecific antibody | EGFR, MET | Phase 1 | Advanced Cancer; RAS/BRAF Wild Type Colorectal Cancer | Dec 2026 |
| AstraZeneca | FPI-2053 Bispecific antibody targeting EGFR and cMET | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| AstraZeneca | [111In]-FPI-2107 Imaging agent (indium-111 conjugated to FPI-2053 bispecific antibody targeting EGFR and cM | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| AstraZeneca | [225Ac]-FPI-2068 Alpha-emitting radiopharmaceutical (actinium-225) conjugated to bispecific antibody target | EGFR, MET | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQB6411 for Injection EGFR/c-Met dual-targeting antibody-drug conjugate | EGFR, MET | Phase 1 | Esophageal Cancer; Advanced Lung Cancer | Feb 2027 |
| Turning Point Therapeutics | elzovantinib (TPX-0022) MET/CSF1R/SRC inhibitor | MET, CSF1R, SRC | Phase 1 | Advanced Solid Tumor | Mar 2027 |
| Shanghai Henlius Biotech | HLX48 EGFR/c-MET bispecific antibody-drug conjugate | EGFR, MET | Phase 1 | Advanced/Metastatic Solid Tumors | Mar 2027 |
| Peking University Cancer Hospital & Institute | Vebreltinib c-MET inhibitor | MET | Phase 1 | Non Small Cell Lung Cancer NSCLC | Apr 2027 |
| Johnson & Johnson (Janssen) | Capmatinib Hepatocyte growth factor receptor inhibitor | MET | Phase 1 | Carcinoma, Non-Small-Cell Lung | Apr 2027 |
| Innovent Biopharmaceutical Technology (Hangzhou) | IBI3028 Recombinant anti-EGFR and c-Met antibodies dual-payload conjugate | EGFR, MET | Phase 1 | Solid Tumor | Jun 2027 |
| Regeneron Pharmaceuticals | REGN5093 (davutamig) MET inhibitor | MET | Phase 1 | NSCLC | Jul 2027 |
| DeuterOncology | DO-2 Deuterated MET kinase inhibitor | MET | Phase 1 | Adult Solid Tumor | Sep 2027 |
| Full-Life Technologies UK | [225Ac]Ac-FL-020 anti-c-MET targeted radioligand therapy (alpha-particle emitter conjugate) | MET | Phase 1 | Metastatic Castration-resistant Prostate Cancer; Solid Tumor | Sep 2027 |
| BeOne Medicines | BG-C0902 Bispecific anti-EGFR and anti-MET antibody-drug conjugate with topoisomerase 1 inhibitor p | EGFR, MET | Phase 1 | Solid Tumors | Nov 2027 |
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB6411 injection EGFR/c-Met dual-targeting antibody-drug conjugate (ADC) | EGFR, MET | Phase 1 | Advanced Malignant Tumors | Dec 2027 |
| Betta Pharmaceuticals | MCLA-129 bispecific antibody targeting EGFR and cMET | EGFR, MET | Phase 1 | Solid Tumor; Solid Advanced Tumor | Apr 2028 |
| Chong Kun Dang Pharmaceutical | CKD-703 c-Met-targeting monoclonal antibody conjugated to monomethyl auristatin E (MMAE) | MET | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2922 injection Bispecific antibody against EGFR and c-Met | EGFR, MET | Phase 1 | Advanced Cancers | Dec 2029 |
| Pierre Fabre Medicament | VERT-002 MET inhibitor | MET | Phase 1 | Solid Tumor | Oct 2030 |
| Merus | MCLA-129 bispecific IgG1 antibody targeting EGFR and c-MET receptor tyrosine kinases | EGFR, MET | Phase 1 | Non-Small Cell Lung Cancer Metastatic | – |
Carcinoma, Non-Small-Cell Lung (12) Non-Small Cell Lung Cancer (9) Non-small Cell Lung Cancer (6) Non-Small-Cell Lung Cancer (5) Advanced Solid Tumor (5) Hepatocellular Carcinoma (5) Colorectal Cancer (5) Solid Tumor (5) Advanced Lymphoma (4) Metastatic Colorectal Cancer (4) Metastatic Renal Cell Carcinoma (4) Recurrent Lung Non-Small Cell Carcinoma (3)
small molecule (33), mixed (8), antibody (2)
AstraZeneca (4) Johnson & Johnson (Janssen) (2) Exelixis (2) AbbVie (2) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (2) Chia Tai Tianqing Pharmaceutical Group (2) Beijing Scitech-Mq Pharmaceuticals (1) IDEAYA Biosciences (1) National Cancer Institute (NCI) (1) Shanghai Henlius Biotech (1) DeuterOncology (1) Pierre Fabre Medicament (1) Turning Point Therapeutics (1) Sichuan Kelun-Biotech Biopharmaceutical (1) Beijing Pearl Biotechnology Limited Liability Company (1) Apollomics (1) M.D. Anderson Cancer Center (1) Betta Pharmaceuticals (1) Shanghai EpimAb Biotherapeutics (1) Yonsei University (1)
EGFR (15) KDR (3) PDGFRA (2) RET (2) ALK (2) EML4 (2) NPM1 (2) ROS1 (2) KIT (2) VEGFR2 (1) AXL (1) CSF1R (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.